Published in TB and Outbreaks Week, June 14th, 2005
The study was conducted by Dr. Ellen Scherl, assistant professor of medicine at Weill Medical College of Cornell University, and colleagues.
The physicians are encouraged by the unexpected results of rifaximin, which was FDA-approved last year for traveler's diarrhea. But, they cautioned, these preliminary findings still...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.